65--Genomic Health/Oncotype DX® Breast Cancer Assay cost per test reportable

DEPARTMENT OF VETERANS AFFAIRS VETERANS INTEGRATED SERVICE NETWORK (VISN) 16 OKLAHOMA CITY VA MEDICAL CENTER REQUEST FOR INFORMATION VA256-16-N-1514 BACKGROUND: The Oklahoma City VA Medical Center (OKC VAMC) Pathology and Laboratory Service intends to pursue a contract for the provision of Oncotype DX® Breast Cancer Assay. The Oncotype DX® Breast Cancer Assay provides personalized information based on tumor biology that can inform treatment decisions that are cost effective. The Oncotype DX® Breast Cancer Assay was developed by and is proprietary to Genomic Health, Inc. The Assay is clinically validated to predict the risk of recurrence for those women with early stage (I, II, IIIa) invasive breast cancer that are estrogen-receptor positive (ER+), human epidermal growth factor receptor negative (Her2-), lymph node negative or positive and predict who may or may not significantly benefit from adjuvant chemotherapy. The Oncotype CX® Breast Cancer Assay is standard of care and has been incorporated in the clinical guidelines of the American Society of Clinical Oncology and the National Comprehensive Cancer Network. The Oklahoma City VAMC has a requirement for the following: Contractor shall: 1. Be College of American Pathologist (CAP) accredited. 2. Hold current Clinical Laboratory Improvement Act (CLIA) certification for high complexity testing. 3. Provide requisitions and any required specialized specimen collection or transport materials. 4. Perform Oncotype DX® Breast Cancer Assay on tissues sent. 5. Provide hard copy results to laboratory when available. III. Performance Period. October 1, 2015 to September 30, 2016. REQUESTED RESPONSES: The intent of this Request for Information (RFI) is to establish sources in order to define the procurement strategy. Interested contractors are requested to respond in accordance with the following 1. Please respond to this RFI if you are capable of providing the listed products. Please cite business size status in the response. 2. Please respond to this RFI if you are capable of providing supplies that can be determined to be EQUIVALENT to the products listed in in the background section above. CONTACT INFORMATION AND RESPONSE DUE DATE: Please email all responses to [email protected]. Please respond to this RFI no later than Monday, September 19, 2016 no later than 7 PM CT. DISCLAIMER: This RFI is issued solely for informational and planning purposes and does not constitute a solicitation. Responses to this notice are not offers and cannot be accepted by the Department of Veterans Affairs to form a binding contract. Respondents are solely responsible for all expenses associated with responding to this RFI.